jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Optinose, Inc.

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Appoints Terry Kohler as Chief Financial Officer
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Expanded Access to XHANCE with Addition to National Commercial Formularies
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces $55 Million Registered Direct Offering
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose to Present at the 2023 Cantor Global Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose to Present at the Jefferies Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News